Table 2.
Most common (≥ 15% of patients; any grade) adverse events, regardless of study drug relationship
| Adverse event, n (%) | All patients (N = 50)a |
|
|---|---|---|
| Any grade | Grade 3/4 | |
| Total | 50 (100) | 35 (70) |
| Diarrhoea | 27 (54) | 2 (4) |
| Nausea | 24 (48) | 2 (4) |
| Decreased appetite | 18 (36) | 0 |
| Increased ALT | 18 (36) | 8 (16) |
| Increased AST | 17 (34) | 6 (12) |
| Fatigue | 16 (32) | 2 (4) |
| Rash | 16 (32) | 5 (10) |
| Cough | 15 (30) | 0 |
| Hyperglycemia | 15 (30) | 2 (4)b |
| Asthenia | 14 (28) | 4 (8) |
| Vomiting | 14 (28) | 1 (2) |
| Stomatitis | 12 (24) | 2 (4) |
| Headache | 11 (22) | 0 |
| Anxiety | 11 (22) | 2 (4) |
| Depression | 9 (18) | 1 (2) |
a
Three patients received a loading dose of trastuzumab but not buparlisib, and are not included here
b
Includes one patient with ‘blood glucose increased’